U.S. markets open in 5 hours 5 minutes

BetterLife Pharma Inc. (BETRF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.2486-0.0064 (-2.51%)
At close: 3:53PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.2550
Open0.2550
BidN/A x N/A
AskN/A x N/A
Day's Range0.2406 - 0.2657
52 Week Range0.1830 - 1.9000
Volume136,814
Avg. Volume147,846
Market Cap21.087M
Beta (5Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-0.8530
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • BetterLife Receives Approval to Conduct COVID-19 Randomized Placebo-Controlled Trial with Pontificia Universidad Católica de Chile
    GlobeNewswire

    BetterLife Receives Approval to Conduct COVID-19 Randomized Placebo-Controlled Trial with Pontificia Universidad Católica de Chile

    VANCOUVER, British Columbia, July 27, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU) today announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), and Pontificia Universidad Católica de Chile have obtained approval from the Instituto de Salud Publica de Chile to conduct their planned randomized placebo-controlled trial (“IN2COVID”) in COVID-19 patients. The trial, set to start in early August, tests

  • BetterLife-Carleton University Research Team Secure Mitacs Accelerate Funding to Study the Therapeutic Effect of TD-010 in Chronic Anxiety
    GlobeNewswire

    BetterLife-Carleton University Research Team Secure Mitacs Accelerate Funding to Study the Therapeutic Effect of TD-010 in Chronic Anxiety

    VANCOUVER, British Columbia, July 22, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on developing compounds to treat neurological conditions, is pleased to announce funding of its joint application with Dr. Argel Aguilar-Valles at Carleton University (“Carleton”) Department of Neuroscience by the Accelerate program at Mitacs for research into the anxiolytic potential of TD-010 in precli

  • CEO Presenting on the Emerging Growth / Investors Hub Joint Conference on July 21; Register Now
    GlobeNewswire

    CEO Presenting on the Emerging Growth / Investors Hub Joint Conference on July 21; Register Now

    Niche Companies in Technology, Gaming, Biotech, Exploration, Oil & Gas and more in AttendanceMIAMI, July 20, 2021 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 12th Emerging Growth Conference. Emerging Growth teams with Investors Hub, one of the top investing websites and apps providing streaming market data tools and over 3